219 related articles for article (PubMed ID: 34061640)
21. Detection of IgG Antibodies to SARS-CoV-2 and Neutralizing Capabilities Using the Luminex
King A; King G; Weiss C; Dunbar S; Das S
Methods Mol Biol; 2022; 2511():257-271. PubMed ID: 35838966
[TBL] [Abstract][Full Text] [Related]
22. Regulatory challenges of convalescent plasma collection during the evolving stages of COVID-19 pandemic in the United States.
Hassan S; West KA; Conry-Cantilena K; De Giorgi V
Transfusion; 2022 Feb; 62(2):483-492. PubMed ID: 34778974
[No Abstract] [Full Text] [Related]
23. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management.
Ochani R; Asad A; Yasmin F; Shaikh S; Khalid H; Batra S; Sohail MR; Mahmood SF; Ochani R; Hussham Arshad M; Kumar A; Surani S
Infez Med; 2021 Mar; 29(1):20-36. PubMed ID: 33664170
[TBL] [Abstract][Full Text] [Related]
24. COVID-19: Main therapeutic options.
Hachfi W; Ben Lasfar N
Tunis Med; 2020 Apr; 98(4):299-303. PubMed ID: 32395792
[No Abstract] [Full Text] [Related]
25. Fast-spreading COVID variant can elude immune responses.
Callaway E
Nature; 2021 Jan; 589(7843):500-501. PubMed ID: 33479534
[No Abstract] [Full Text] [Related]
26. Audio Interview: Planning for the SARS-CoV-2 Vaccine Rollout.
Rubin EJ; Baden LR; Lee TH; Morrissey S
N Engl J Med; 2021 Jan; 384(1):e13. PubMed ID: 33406335
[No Abstract] [Full Text] [Related]
27. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ
Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627
[TBL] [Abstract][Full Text] [Related]
28. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex.
Zeng F; Dai C; Cai P; Wang J; Xu L; Li J; Hu G; Wang Z; Zheng F; Wang L
J Med Virol; 2020 Oct; 92(10):2050-2054. PubMed ID: 32383183
[TBL] [Abstract][Full Text] [Related]
29. Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa.
Giorgino F; Bhana S; Czupryniak L; Dagdelen S; Galstyan GR; Janež A; Lalić N; Nouri N; Rahelić D; Stoian AP; Raz I
Diabetes Res Clin Pract; 2021 Feb; 172():108617. PubMed ID: 33310175
[TBL] [Abstract][Full Text] [Related]
30. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
31. One year into the clash of pandemics of diabetes and COVID-19: Lessons learnt and future perspectives.
Lui DTW; Lee CH; Tan KCB
J Diabetes Investig; 2022 Jan; 13(1):19-21. PubMed ID: 34375500
[TBL] [Abstract][Full Text] [Related]
32. Audio Interview: Efficacy of Current Covid-19 Vaccines against Variant Viruses.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Mar; 384(11):e53. PubMed ID: 33730461
[No Abstract] [Full Text] [Related]
33. Convalescent plasma to treat COVID-19: clinical experience and efficacy.
Pei S; Yuan X; Zhang Z; Yao R; Xie Y; Shen M; Li B; Chen X; Yin M
Aging (Albany NY); 2021 Mar; 13(6):7758-7766. PubMed ID: 33735836
[TBL] [Abstract][Full Text] [Related]
34. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19.
Majumder J; Minko T
AAPS J; 2021 Jan; 23(1):14. PubMed ID: 33400058
[TBL] [Abstract][Full Text] [Related]
35. Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium.
Rello J; Belliato M; Dimopoulos MA; Giamarellos-Bourboulis EJ; Jaksic V; Martin-Loeches I; Mporas I; Pelosi P; Poulakou G; Pournaras S; Tamae-Kakazu M; Timsit JF; Waterer G; Tejada S; Dimopoulos G
Anaesth Crit Care Pain Med; 2020 Dec; 39(6):723-730. PubMed ID: 33172592
[TBL] [Abstract][Full Text] [Related]
36. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
[TBL] [Abstract][Full Text] [Related]
37. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
38. Analysis of COVID-19 convalescent plasma for SARS-CoV-2 IgG using two commercial immunoassays.
DomBourian MG; Annen K; Huey L; Andersen G; Merkel PA; Jung S; Dominguez SR; Knight V
J Immunol Methods; 2020 Nov; 486():112837. PubMed ID: 32828791
[TBL] [Abstract][Full Text] [Related]
39. Telemedicine for the Clinical Management of Diabetes; Implications and Considerations After COVID-19 Experience.
de Kreutzenberg SV
High Blood Press Cardiovasc Prev; 2022 Jul; 29(4):319-326. PubMed ID: 35579849
[TBL] [Abstract][Full Text] [Related]
40. Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients.
Valleriani F; Mancuso E; Vincifori G; Teodori L; Di Marcantonio L; Spedicato M; Leone A; Savini G; Morelli D; Bonfini B; Lorusso A
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
